Story perspectives

Trump Adds 9 Pharma Firms to MFN Drug Plan

9/1/2026

Summary

Trump Expands MFN

U.S. President Donald Trump announced nine additional pharmaceutical companies joining his most-favored-nation drug-pricing initiative.
The additions bring the program to 26 firms covering roughly 90 % of the U.S. market.
The companies pledged at least $19.6 billion for new U.S. drug manufacturing.
Trump said the deals should save Americans over $600 billion.
MFN agreements cap U.S. drug prices at the lowest OECD rates and grant tax, tariff and regulatory benefits.

Summary

Trump Saves

Prescription-drug CPI fell 0.8%, the steepest annual drop since 1963.
President Donald Trump's TrumpRx platform saved consumers $700 million since its February launch.
BeOne Medicines pledged nearly $11 billion for U.S. R&D and manufacturing through 2029.
Kyowa Kirin aims for over 95% of its U.S.-made drugs to be designated for American patients within two years.
Roughly 30,000 rare diseases exist worldwide, but treatments cover only 10%.

History

Historical Context

The 2003 Medicare Prescription Drug, Improvement, and Modernization Act, signed by President George W. Bush and championed by Senator Bill Frist, created Medicare Part D, giving about 45 million seniors coverage when it began in 2006 and earmarking roughly $400 billion in subsidies. Because the law barred federal price negotiation, later proposals such as President Trump’s MFN platform seek broader manufacturing pledges to curb drug spending.

1 of 3

Trump Expands MFN

U.S. President Donald Trump announced nine additional pharmaceutical companies joining his most-favored-nation drug-pricing initiative.
The additions bring the program to 26 firms covering roughly 90 % of the U.S. market.
The companies pledged at least $19.6 billion for new U.S. drug manufacturing.
Trump said the deals should save Americans over $600 billion.
MFN agreements cap U.S. drug prices at the lowest OECD rates and grant tax, tariff and regulatory benefits.

1 / 3